Ilumya FDA Approval History
FDA Approved: Yes (First approved March 20, 2018)
Brand name: Ilumya
Generic name: tildrakizumab-asmn
Dosage form: Injection
Company: Sun Pharmaceutical Industries Inc.
Treatment for: Plaque Psoriasis
Ilumya (tildrakizumab-asmn) is a humanized, anti-IL-23p19 monoclonal antibody for the treatment of moderate-to-severe plaque psoriasis.
Development timeline for Ilumya
|Mar 21, 2018||Approval FDA Approves Ilumya (tildrakizumab-asmn) for the Treatment of Moderate-to-Severe Plaque Psoriasis|
|May 24, 2017||Sun Pharma Announces US FDA Filing Acceptance of Biologics License Application (BLA) For Tildrakizumab|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.